Outset Medical's third quarter of 2025 saw a revenue of $36.2 million, a 10% increase year-over-year, driven by strong product revenue. Despite the revenue growth, the company reported a net loss of $23.1 million and a non-GAAP net loss of $18.5 million. Gross margin improved to 25.4%, and the Tablo installed base grew to 4,000 units.
Revenue for Q3 2025 increased by 10% year-over-year to $36.2 million.
The company reported a net loss of $23.1 million and a non-GAAP net loss of $18.5 million.
Gross margin improved to 25.4%, up from 20.1% in the prior year period.
The Tablo installed base expanded to 4,000 units, marking a 25% increase year-over-year.
Outset Medical provided updated full-year 2025 guidance, projecting revenue between $140 million and $145 million, and a non-GAAP net loss between $75 million and $80 million. The company expects continued growth in its Tablo installed base and recurring revenue.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance